Therapy Finder – Professional

Genetic mutations can contribute to lung cancer growth. This tool uses mutational status to help identify potentially relevant therapies.

The EGFR gene if often aberrant in adenocarcinomas and sometimes in squamous and large cell carcinoma.

The KRAS gene is commonly mutated in lung adenocarcinomas.

ALK has been shown to make oncogenic fusions with other genes in lung cancer. ALK positive refers to the presence of an ALK translocation.

ROS1 is a fusion gene that has been observed predominantly in adenocarcinomas.

VeriStrat is a blood test that predicts responsiveness to certain drugs such as EGFR inhibitors.

Several drugs that target these aberrations are approved and some are in clinical trials for lung cancer.